

HÃ¥kan Mellstedt

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/840263/publications.pdf>

Version: 2024-02-01

99
papers

3,365
citations

172457

29
h-index

155660

55
g-index

100
all docs

100
docs citations

100
times ranked

4314
citing authors

#	ARTICLE	IF	CITATIONS
1	Therapeutic vaccines for cancer: an overview of clinical trials. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 509-524.	27.6	636
2	Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 1996, 93, 151-153.	2.5	219
3	Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. <i>International Journal of Cancer</i> , 2008, 123, 1190-1195.	5.1	154
4	Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. <i>International Journal of Cancer</i> , 1996, 69, 114-119.	5.1	123
5	T cells in chronic lymphocytic leukemia display dysregulated expression of immune checkpoints and activation markers. <i>Haematologica</i> , 2017, 102, 562-572.	3.5	121
6	Effect of monoclonal antibody 17-1A and gm-CSF in patients with advanced colorectal carcinoma—long-lasting, complete remissions can be induced. <i>International Journal of Cancer</i> , 1993, 53, 751-758.	5.1	94
7	Modulation of anti-idiotypic immune response by immunization with the autologous M μ component protein in multiple myeloma patients. <i>British Journal of Haematology</i> , 1996, 92, 840-846.	2.5	92
8	Pharmacological administration of granulocyte/macrophage-colony-stimulating factor is of significant importance for the induction of a strong humoral and cellular response in patients immunized with recombinant carcinoembryonic antigen. <i>Cancer Immunology, Immunotherapy</i> , 1998, 47, 131-142.	4.2	92
9	The receptor tyrosine kinase ROR1—An oncofetal antigen for targeted cancer therapy. <i>Seminars in Cancer Biology</i> , 2014, 29, 21-31.	9.6	85
10	Silencing of <i>ROR1</i> and <i>FMOD</i> with siRNA results in apoptosis of CLL cells. <i>British Journal of Haematology</i> , 2010, 151, 327-335.	2.5	67
11	Orphan receptor tyrosine kinases ROR1 and ROR2 in hematological malignancies. <i>Leukemia and Lymphoma</i> , 2013, 54, 843-850.	1.3	67
12	Interferon and natural killer activity in multiple myeloma. Lack of correlation between interferon-induced enhancement of natural killer activity and clinical response to human interferon- γ . <i>International Journal of Cancer</i> , 1982, 30, 167-172.	5.1	63
13	T cell repertoire in patients with multiple myeloma and monoclonal gammopathy of undetermined significance: Clonal CD8+ T cell expansions are found preferentially in patients with a low tumor burden. <i>European Journal of Immunology</i> , 1997, 27, 2245-2252.	2.9	60
14	Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A. <i>Cancer Immunology, Immunotherapy</i> , 1996, 42, 81-87.	4.2	59
15	Telomerase (GV1001) vaccination together with gemcitabine in advanced pancreatic cancer patients. <i>International Journal of Oncology</i> , 2014, 45, 1293-1303.	3.3	56
16	Vaccines for the treatment of non-small cell lung cancer: Investigational approaches and clinical experience. <i>Lung Cancer</i> , 2011, 73, 11-17.	2.0	55
17	T and B cells in B-chronic lymphocytic leukaemia: Faust, Mephistopheles and the pact with the Devil. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 210-220.	4.2	50
18	Telomerase (hTERT 611—626) serves as a tumor antigen in B-cell chronic lymphocytic leukemia and generates spontaneously antileukemic, cytotoxic T cells. <i>Experimental Hematology</i> , 2007, 35, 297-304.	0.4	50

#	ARTICLE	IF	CITATIONS
19	Intracellular T cell cytokines in patients with B cell chronic lymphocytic leukaemia (B-CLL). <i>European Journal of Haematology</i> , 2002, 68, 299-306.	2.2	46
20	Vaccination with dendritic cells loaded with tumor apoptotic bodies (Apo-DC) in patients with chronic lymphocytic leukemia: effects of various adjuvants and definition of immune response criteria. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 865-879.	4.2	46
21	Glioblastoma-synthesized G-CSF and GM-CSF contribute to growth and immunosuppression: Potential therapeutic benefit from dapsone, fenofibrate, and ribavirin. <i>Tumor Biology</i> , 2017, 39, 101042831769979.	1.8	45
22	T-cell-epitope mapping of the idiotypic monoclonal IgG heavy and light chains in multiple myeloma. , 1999, 80, 671-680.		43
23	Clinical considerations for biosimilar antibodies. <i>European Journal of Cancer, Supplement</i> , 2013, 11, 1-11.	2.2	42
24	Interleukin-10 mRNA expression in B-cell chronic lymphocytic leukaemia inversely correlates with progression of disease. <i>British Journal of Haematology</i> , 1996, 92, 393-400.	2.5	37
25	Dendritic cell regulation of NK cell responses involves lymphotoxin-1, IL-12, and TGF- β^2 . <i>European Journal of Immunology</i> , 2015, 45, 1783-1793.	2.9	34
26	Patients treated with a monoclonal antibody (ab1) to the colorectal carcinoma antigen 17-1A develop a cellular response (DTH) to the internal image of the antigen (ab2). <i>International Journal of Cancer</i> , 1991, 48, 344-349.	5.1	33
27	Monoclonal Blood Lymphocytes in Benign Monoclonal Gammopathy and Multiple Myeloma in Relation to Clinical Stage. <i>Scandinavian Journal of Haematology</i> , 1981, 27, 287-293.	0.0	32
28	The PI3K/AKT/mTOR pathway is involved in direct apoptosis of CLL cells induced by ROR1 monoclonal antibodies. <i>British Journal of Haematology</i> , 2015, 169, 455-458.	2.5	32
29	Longitudinal studies of blood lymphocyte capacity in Hodgkin's disease. <i>Cancer</i> , 1981, 48, 2010-2015.	4.1	31
30	Clonal cell surface structures related to differentiation, activation and homing in B-cell chronic lymphocytic leukemia and monoclonal lymphocytosis of undetermined significance. <i>European Journal of Haematology</i> , 1989, 43, 452-459.	2.2	30
31	Increased serum levels of soluble Fas in progressive B-CLL. <i>European Journal of Haematology</i> , 2001, 66, 342-346.	2.2	29
32	Overexpression of the epithelial cell adhesion molecule is associated with a more favorable prognosis and response to platinum-based chemotherapy in ovarian cancer. <i>Journal of Gynecologic Oncology</i> , 2014, 25, 221.	2.2	29
33	Increased LAK and T cell activation in responding renal cell carcinoma patients after low dose cyclophosphamide, IL-2 and \pm -IFN. <i>Medical Oncology</i> , 1995, 12, 69-77.	2.5	28
34	Blood clonal B-cell excess in patients with monoclonal gammopathy of undetermined significance (MGUS): association with malignant transformation. <i>British Journal of Haematology</i> , 1996, 92, 71-76.	2.5	28
35	Chromosome 13q \downarrow new marker for B-cell chronic lymphocytic leukemia. <i>Hereditas</i> , 1988, 108, 77-84.	1.4	28
36	A receptor tyrosine kinase ROR1 inhibitor (KAN0439834) induced significant apoptosis of pancreatic cells which was enhanced by erlotinib and ibrutinib. <i>PLoS ONE</i> , 2018, 13, e0198038.	2.5	27

#	ARTICLE	IF	CITATIONS
37	Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia. <i>British Journal of Haematology</i> , 2000, 111, 230-238.	2.5	26
38	Dendritic cells in patients with non-progressive B-chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern. <i>British Journal of Haematology</i> , 2001, 115, 263-271.	2.5	25
39	The large sialoglycoprotein of human lymphocytes. I. Distribution on T and B lineage cells as revealed by a monospecific chicken antibody. <i>European Journal of Immunology</i> , 1985, 15, 417-426.	2.9	24
40	Dishevelled proteins are significantly upregulated in chronic lymphocytic leukaemia. <i>Tumor Biology</i> , 2016, 37, 11947-11957.	1.8	24
41	Oral melphalan pharmacokinetics & relation to dose in patients with multiple myeloma. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1989, 6, 151-154.	1.1	22
42	Human monoclonal immunoglobulins that bind the human acetylcholine receptor. <i>European Journal of Immunology</i> , 1987, 17, 1867-1869.	2.9	21
43	Progressive B-cell chronic lymphocytic leukaemia frequently exhibits aberrant p53 expression. <i>International Journal of Cancer</i> , 1994, 58, 474-479.	5.1	21
44	Ibrutinib-A double-edge sword in cancer and autoimmune disorders. <i>Journal of Drug Targeting</i> , 2016, 24, 373-385.	4.4	21
45	B-CLL cells with unusual properties. , 1997, 70, 1-8.		20
46	ROR1 is Expressed in Diffuse Large B-Cell Lymphoma (DLBCL) and a Small Molecule Inhibitor of ROR1 (KAN0441571C) Induced Apoptosis of Lymphoma Cells. <i>Biomedicines</i> , 2020, 8, 170.	3.2	19
47	Oral melphalan pharmacokinetics: Influence of interferon-induced fever. <i>Clinical Pharmacology and Therapeutics</i> , 1990, 47, 86-90.	4.7	18
48	Expression of Adhesion Molecules CD 11/CD 18 (Leu-CAMs, β 2-Integrins), CD54 (ICAM-1) and CD58 (LFA-3) in B-Chronic Lymphocytic Leukemia. <i>Leukemia and Lymphoma</i> , 1994, 13, 297-306.	1.3	18
49	(D)-Penicillamine Treatment in Systemic Sclerosis (Scleroderma): Effect on Nutritional Capillary Circulation. <i>Scandinavian Journal of Rheumatology</i> , 1977, 6, 92-96.	1.1	17
50	Immune deficiency in family members of patients with Hodgkin's disease. <i>Cancer</i> , 1990, 66, 1938-1943.	4.1	16
51	T cells from indolent CLL patients prevent apoptosis of leukemic B cells in vitro and have altered gene expression profile. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 51-63.	4.2	16
52	Clinical and Immune Effects of Lenalidomide in Combination with Gemcitabine in Patients with Advanced Pancreatic Cancer. <i>PLoS ONE</i> , 2017, 12, e0169736.	2.5	16
53	Comparison of daunorubicin and daunorubicin-DNA complex in the treatment of acute nonlymphoblastic leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 1981, 6, 65-73.	2.3	15
54	Clonality and methylation status of the Epstein-Barr virus (EBV) genomes in V7W-infected EBV-carrying chronic lymphocytic leukemia (CLL) cell lines. <i>International Journal of Cancer</i> , 1991, 48, 62-66.	5.1	15

#	ARTICLE	IF	CITATIONS
55	Long-Term Influence of Splenectomy on Immune Functions in Patients with Hodgkin's Disease. <i>Scandinavian Journal of Haematology</i> , 1980, 24, 87-94.	0.0	15
56	Lymphocytotoxic serum factors and lymphocyte functions in untreated Hodgkin'S disease. <i>Cancer</i> , 1982, 50, 2044-2048.	4.1	13
57	Epstein barr virus (EBV)-carrying cells of a chronic lymphocytic leukemia (CLL) subpopulation express EBNA1 and LMPS but not EBNA2in vivo. <i>International Journal of Cancer</i> , 1995, 63, 486-490.	5.1	13
58	Lenalidomide as immune adjuvant to a dendritic cell vaccine in chronic lymphocytic leukemia patients. <i>European Journal of Haematology</i> , 2018, 101, 68-77.	2.2	13
59	Polymorphisms within methotrexate pathway genes: Relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia. <i>Iranian Journal of Basic Medical Sciences</i> , 2020, 23, 800-809.	1.0	13
60	Fine-Needle Aspiration Cytology with Immunocytochemistry of Extranodal Manifestations of Non-Hodgkin's Lymphoma. <i>Leukemia and Lymphoma</i> , 1990, 1, 129-139.	1.3	12
61	Biosimilars – terms of use. <i>Current Medical Research and Opinion</i> , 2015, 31, 2325-2330.	1.9	12
62	Spontaneous Immunity Against the Receptor Tyrosine Kinase ROR1 in Patients with Chronic Lymphocytic Leukemia. <i>PLoS ONE</i> , 2015, 10, e0142310.	2.5	12
63	Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung. <i>Cell Death and Disease</i> , 2021, 12, 577.	6.3	11
64	Chemotherapy and immunotherapy of colorectal cancer. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1991, 8, 207-20.	1.1	11
65	Epstein-Barr virus (EBV) gene expression in lymphoid B cells during acute infectious mononucleosis (IM) and clonality of the directly growing cell lines. , 1997, 71, 345-349.		10
66	IRON INTOXICATION IN TWO ADULT PATIENTS. <i>Acta Medica Scandinavica</i> , 1974, 196, 231-236.	0.0	10
67	Treatment of multiple myeloma with natural β -interferon. <i>Hematological Oncology</i> , 1988, 6, 187-192.	1.7	9
68	Blood Lymphocyte Functions in Relation to Splenic Weight and Tumor Involvement in Untreated Hodgkin's Disease. <i>Scandinavian Journal of Haematology</i> , 1981, 25, 51-57.	0.0	9
69	Phase II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 91-102.	4.2	9
70	Differential expression of viral agents in lymphoma tissues of patients with ABC diffuse large B-cell lymphoma from high and low endemic infectious disease regions. <i>Oncology Letters</i> , 2016, 12, 2782-2788.	1.8	7
71	T Cells from Patients with Chronic Lymphocytic Leukaemia Prevent Apoptosis of Autologous CLL Cells in a Dose- and Cell:Cell-Contact Dependent Fashion; Rationale for New Therapeutic Possibilities.. <i>Blood</i> , 2008, 112, 2071-2071.	1.4	7
72	Prednimustine and vincristine compared with cytosine arabinoside and thioguanine for treatment of elderly patients with acute nonlymphoblastic leukemia. <i>Cancer Chemotherapy and Pharmacology</i> , 1982, 9, 89-92.	2.3	6

#	ARTICLE	IF	CITATIONS
73	bcl-2 rearrangement detected by pulsed-field gel electrophoresis (PFGE) in B-chronic lymphocytic leukemia (CLL) cells. , 1998, 76, 909-912.		6
74	Targeting the Receptor Tyrosine Kinase ROR1 by Small Molecules. Handbook of Experimental Pharmacology, 2021, 269, 75-99.	1.8	5
75	Clinical and laboratory findings in untreated patients with Hodgkin's disease with special reference to age. Medical Oncology and Tumor Pharmacotherapy, 1984, 1, 33-41.	1.1	5
76	Analysis of HLA-G gene expression in B-lymphocytes from chronic lymphocytic leukemia patients. Iranian Biomedical Journal, 2007, 11, 125-129.	0.7	5
77	Dual targeting of Bruton tyrosine kinase and CD52 induces minimal residual disease negativity in the bone marrow of poor-prognosis chronic lymphocytic leukaemia patients but is associated with opportunistic infections Results from a phase I study. British Journal of Haematology. 2018. 182. 590-594.	2.5	3
78	A ROR1 small molecule inhibitor (KAN0441571C) induced significant apoptosis of ibrutinib-resistant ROR1 CLL cells. EJHaem, 2021, 2, 498-502.	1.0	3
79	ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Mantle Cell Lymphoma (MCL) Cells. Blood, 2019, 134, 5312-5312.	1.4	3
80	In Vivo Effects of Lenalidomide on T Cell Proliferation and Immune Checkpoint Molecules in Patients with Advanced Stage CLL: Results from a Phase II Study. Blood, 2015, 126, 4164-4164.	1.4	3
81	Effect of ROR1-targeting small molecules on chronic lymphocytic leukemia (CLL) cells.. Journal of Clinical Oncology, 2012, 30, 6557-6557.	1.6	3
82	Autologous T cells expressing the oncogenic transcription factor KLF6-SV1 prevent apoptosis of chronic lymphocytic leukemia cells. PLoS ONE, 2018, 13, e0192839.	2.5	3
83	Buoyant density characterization of neoplastic cell populations in patients with chronic B-lymphocytic leukemia. European Journal of Haematology, 1988, 40, 142-148.	2.2	2
84	CORRELATION OF IMMUNOPHENOTYPE TO MORPHOLOGY IN UNFAVOURABLE NON-HODGKIN LYMPHOMA. Acta Pathologica, Microbiologica, Et Immunologica Scandinavica Section A, Pathology, 1983, 91A, 425-433.	0.3	2
85	Temporary cessation of ibrutinib results in reduced grade 3&4 infections and durable remissions Interim analysis of an on-off-repeat Phase 1b/2 study in patients with chronic lymphocytic leukemia. EJHaem, 2021, 2, 525-529.	1.0	2
86	Bcl2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. International Journal of Cancer, 1996, 69, 114-119.	5.1	2
87	First-in-Class ROR1 Small Molecule Inhibitor (KAN0439834) Downregulated Wnt-Canonical and Non-Canonical Signaling Pathways and Induced Apoptosis of CLL Cells. Blood, 2015, 126, 2912-2912.	1.4	2
88	Apoptosis induction mediated through PI3-kinase/AKT/mTOR pathway using anti-ROR1 monoclonal antibody in chronic lymphocytic leukemia cells.. Journal of Clinical Oncology, 2013, 31, 7087-7087.	1.6	2
89	Induction of a T- and B-cell response against a unique amino acid sequence of the mouse IgG2A hinge region in a MAb-treated patient. , 1997, 73, 790-794.		1
90	Vaccination with Dendritic Cells Loaded with Autologous Leukemic Cells in Combination with Low-Dose Lenalidomide Induced Immune Responses in Chronic Lymphocytic Leukemia (CLL) Patients. Blood, 2014, 124, 4685-4685.	1.4	1

#	ARTICLE	IF	CITATIONS
91	Future Aspects of Cancer Treatment: The Use of Monoclonal Antibodies. International Journal of Technology Assessment in Health Care, 1985, 1, 921-926.	0.5	0
92	Autologous T lymphocytes recognize the tumour-derived immunoglobulin VH-CDR3 region in patients with B-cell chronic lymphocytic leukaemia. British Journal of Haematology, 2000, 111, 230-238.	2.5	0
93	Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia. British Journal of Haematology, 2000, 111, 608-617.	2.5	0
94	Metabolic intervention targeting 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3) using a structure-based design.. Journal of Clinical Oncology, 2012, 30, e13518-e13518.	1.6	0
95	Prognostic value of epithelial cell adhesion molecule (EpCAM) in patients with primary epithelial ovarian cancer.. Journal of Clinical Oncology, 2012, 30, e15531-e15531.	1.6	0
96	Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells.. Journal of Clinical Oncology, 2013, 31, e22198-e22198.	1.6	0
97	Reduction of Tumor Burden Rather Than Off-Target Effects Drives Changes in T-Cell Number and Profile during Prolonged Ibrutinib Treatment in Relapsed or Refractory Chronic Lymphocytic Leukemia Patients. Blood, 2018, 132, 4421-4421.	1.4	0
98	Diffuse Large B Cell Lymphoma (DLBCL) Expresses ROR1 and a ROR1 Small Molecule Inhibitor (KAN0441571C) Induced Significant Apoptosis of Tumor Cells. Blood, 2019, 134, 2565-2565.	1.4	0
99	Expression of the Fractalkine Receptor (CX3CR1) Is Significantly Increased in Immune Cells of Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma patients with Active Disease. Blood, 2019, 134, 5445-5445.	1.4	0